What long-term trends can investors expect from CLB's EPS?

Core Laboratories (CLB) has shown volatile earnings per share (EPS) over the past decade, with a notable decline in EPS from 2019 to 2020. However, there are some long-term trends that investors can expect: 1. **Decline in EPS from 2019 to 2020**: The EPS dropped significantly from $2.28 in 2019 to -$2.2 in 2020, which is a substantial decrease that investors should be aware of. 2. **Recovery from 2020 to 2023**: After the initial decline, there was a recovery in EPS, although it did not reach the previous peak. The EPS for 2023 was $0.77, which is a positive sign indicating a recovery from the previous year's negative performance. 3. **Stability from 2023 to 2024**: The EPS remained relatively stable from 2023 to 2024, with a slight increase to $0.66 in 2024. This suggests a period of stability after the recovery, which could be indicative of a more consistent performance going forward. In conclusion, while CLB's EPS has experienced a significant decline, it has shown signs of recovery and stability in recent years. Investors should monitor the company's performance closely, especially in light of the volatility observed over the past decade. |code|Ticker|Name|Date|Diluted EPS (FY) YoY|Diluted EPS (FY)|market_code| |---|---|---|---|---|---|---| |CLB|CLB.N|Core Laboratories|2015|-53.5528596187175|2.68|169| |CLB|CLB.N|Core Laboratories|2016|-45.5223880597015|1.46|169| |CLB|CLB.N|Core Laboratories|2017|28.767123287671232|1.88|169| |CLB|CLB.N|Core Laboratories|2018|-4.787234042553185|1.79|169| |CLB|CLB.N|Core Laboratories|2019|27.37430167597764|2.28|169| |CLB|CLB.N|Core Laboratories|2020|-196.49122807017548|-2.2|169| |CLB|CLB.N|Core Laboratories|2021|119.54545454545456|0.43|169| |CLB|CLB.N|Core Laboratories|2022|-2.325581395348839|0.42|169| |CLB|CLB.N|Core Laboratories|2023|83.33333333333334|0.77|169| |CLB|CLB.N|Core Laboratories|2024|-14.285714285714285|0.66|169|